GPP
AMAG

Great Point Partners’s AMAG Pharmaceuticals AMAG Stock Holding History

Great Point Partners’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-664,681
Closed -$10.1M – 54
2018
Q4 		$10.1M Buy
+664,681
New +$12.7M 1.28% 27

Other funds holding AMAG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Great Point Partners's AMAG Position: Q1 2019 in Review

Great Point Partners sold out of AMAG Pharmaceuticals (AMAG) in Q1 2019, closing a stake of 664,681 shares — an estimated $10.1M sold.

Great Point Partners first reported a position in AMAG in Q4 2018 and held it in 1 quarter. The position peaked at $10.1M in Q4 2018. 166 funds tracked by Wall St. Rank hold AMAG as of Q1 2019.

  • Great Point Partners reported no remaining AMAG Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Great Point Partners sold 664,681 AMAG Pharmaceuticals shares in Q1 2019, an estimated $10.1M.
  • Great Point Partners first reported a position in AMAG Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Great Point Partners's AMAG Pharmaceuticals position peaked at $10.1M in Q4 2018.
  • 166 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q1 2019.

Based on Great Point Partners's 13F filing for Q1 2019, filed 14 May 2019.